Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)‑positive advanced salivary duct carcinoma: A case report-Reference-Cited by-同舟云学术

Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)‑positive advanced salivary duct carcinoma: A case report

Published:2019-06-10 Issue: Volume: Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:mol clin onc

Author:

Gibo Takahiko¹,Sekiguchi Nodoka²,Gomi Daisuke²,Noguchi Takuro²,Fukushima Toshirou²,Kobayashi Takashi²,Ozawa Takesumi²,Yamada Shin‑Ichi¹,Koizumi Tomonobu²

Affiliation:

1. Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Nagano 390‑8621, Japan

2. Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390‑8621, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-targeted therapies for salivary gland cancers;Oral Oncology;2024-01

2. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta‐Analysis;The Laryngoscope;2022-05-14

3. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing;Modern Pathology;2021-12-28

4. Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target;Head and Neck Pathology;2021-04-22

5. Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity;Frontiers in Pharmacology;2021-03-04